Observed Signal · Nov 11, 2026 · Funding · Source: Tech.eu (European Tech & Deals) · Impact: 1/5 · Sentiment: Positive
Switchpoint Bio Raises $5.3M for Drug Response Insights
Switchpoint Bio, a Helsinki-Cambridge biotech startup, emerged from stealth with $5.3 million in pre-seed funding, including a $5 million investment from Treehouse Delmar Investments. The company combines precision epigenomic profiling and AI to measure disease and treatment-induced biological changes from blood samples, aiming to provide drug developers with insights into patient responses. The platform targets DNA methylation in epigenomically active regions, offering scalable, cost-efficient coverage for drug development. Founded by Samuel Myllykangas and Jason Buenrostro, the team is validating its approach in autoimmune diseases like lupus while engaging pharma partners. The funding will support clinical validation, platform development, and team expansion.
Funding of a biotech startup outside the AdTech industry, with no direct relevance to advertising or marketing technology.
Track Real-Time Financials Signals & Market Shifts
Polaris7 autonomous intelligence agents track regulatory filings, primary sources, executive changes, and deal flow 24/7. Create your Polaris7 workspace to monitor these entities.
Key Takeaways & Evidence Grounding
- Switchpoint Bio raised $5.3 million in a pre-seed financing round.
- Treehouse Delmar Investments contributed $5 million of the total funding.
- The company will use funds for clinical validation, platform development, and team expansion.
- Switchpoint Bio is testing its approach in systemic lupus erythematosus (SLE).
- The company is in talks with pharmaceutical and biotechnology companies for validation programs.
Ontology Mapping & Concepts
Related Market Signals & Shifts
Recent verified developments and strategic activity across this market segment.
Atlas Bio Raises $12.5M for AI Clinical Trial Simulations
Swiss biotech startup Atlas Bio emerged from stealth with a total of $12.5 million in funding to develop an AI foundation model for in-silico clinical trials. The Seed round of $10 million was led by Creandum, with participation from First Momentum Ventures and LEA Partners, who also led a previously undisclosed pre-Seed round of $2.5 million. The company's model, trained on 2 million human RNA readouts, simulates patient-level drug efficacy and safety, aiming to replace Phase II trials and animal testing. Atlas Bio is already working with a top-10 global pharma company and a Basel-based biotech client that has eliminated animal testing in a specific workflow. The founders, Simon Romanski and Sebastian Bayer, emphasize the potential to reduce drug development costs and timelines significantly.
UK startup Pharosyn raises €2.5 million for pharma competitive intelligence platform
London-based Pharosyn, an AI-powered competitive intelligence platform for biopharma, has raised €2.5 million in a funding round led by Moonfire, with participation from Entrepreneurs First, Transpose Platform, and General Advance. The company plans to expand its platform and support wider adoption across pharmaceutical commercial and portfolio strategy teams. Founded in 2025 by Stephen Cowley and Joshua Hampson, Pharosyn monitors clinical, regulatory, and commercial data sources to produce strategic reports tailored to an organisation's pipeline. The funding is part of a broader trend of AI investment in pharma, with EU-Startups reporting approximately €75.3 million across seven comparable rounds this year.
Proximal Ventures Raises $27.5M for AI Drug Development Fund
Proximal Ventures, founded by former SignalFire investor Sahir Raoof, has raised $27.5 million for its debut venture capital fund. The fund will invest in pre-seed and seed-stage startups applying AI to drug development tools, infrastructure, and services. Proximal has already backed seven startups, including ChronicleBio, which uses AI to analyze biological and medical data for chronic disease research. The fund's backers include SignalFire, Kleiner Perkins, Bertelsmann Healthcare Investments, and individual investors like Dimension Capital co-founders. Raoof, who previously worked at Flatiron Health and Iterative Health, aims to capture pharmaceutical spending by offering AI-driven services that are faster and cheaper than traditional outsourcing. The fund will write checks between $500,000 and $1.5 million.
Receive all future signals for Financials in your executive briefing
Never miss material M&A deals, leadership changes, account wins, or product rollouts. Polaris7 monitors 20,000+ primary sources 24/7, delivering verified telemetry directly into your executive briefing.
